Interventional Pulmonology is expected to increase the bronchoscopy market to approximately $180 million in 2012, according to Millennium Research
WALTHAM, Mass., April 7, 2008 /PRNewswire/ -- According to Millennium Research Group's US Markets for ENT & Bronchoscopy 2008 report, an emerging field -- interventional pulmonology -- is creeping into the bronchoscopy market, and is expected to grow the overall market to $180 million by 2012.
To date, the majority of bronchoscopy procedures have been performed to diagnose pulmonary conditions such as lung cancer and chronic lung disease. A number of medical devices that can be used to treat lung-related conditions are, however, awaiting FDA approval. If these therapeutic devices are approved, bronchoscopy procedure volumes in the US will expand as pulmonologists and thoracic surgeons gain the ability to both diagnose and treat lung-related conditions using minimally invasive techniques. Because many interventional pulmonology procedures will be performed with a flexible bronchoscope, therapeutic device approval will also fuel demand for flexible bronchoscopes and other conventional bronchoscopy devices.
Asthmatx' Alair System, which was developed to treat severe asthma cases, will be submitted for FDA premarket approval in 2008. Its approval will add bronchial thermoplasty to the list of treatments that can be performed with flexible bronchoscopy.
"To date, clinical studies performed with the system have showed favorable results," says Tiffanie Demone, Analyst at Millennium Research Group. "A study published in the New England Journal of Medicine in March 2007 found that patients who underwent a bronchial thermoplasty used less rescue medication such as that found in inhalers and showed improvements to their quality of life. Moreover, there were almost 2.5 million severe asthma patients in the US in 2007 who could potentially benefit from bronchial thermoplasty."
The US Markets for ENT & Bronchoscopy 2008 report provides coverage of key industry competitors, including Arthrocare, Boston Scientific, Medtronic, and Olympus.
About Interventional Pulmonology
Interventional pulmonology is the treatment of breathing-related disorders such as asthma, lung cancer, chronic obstructive pulmonary disease, and emphysema. Paralleling the interventional cardiology market in the 1980s, the development of interventional pulmonology is changing the role of a pulmonologist from diagnostician to therapeutic interventionalist. A number of interventional pulmonology device developers formed over the last few years, including Emphasys Medical, Asthmatx, Spiration, Pulmonx, PneumRx, and superDimension. The approval and adoption of medical devices developed by these companies will expand the interventional pulmonology market in the coming years.
About Millennium Research Group
Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Millennium Research Group
|SOURCE Millennium Research Group|
Copyright©2008 PR Newswire.
All rights reserved